Search Page
Filters
Search Results
714 results
Results are displayed in a computed author sort order.
The Publication Date timeline is not available.
Page 1
ICAAC update on opportunistic infections.
Posit Aware. 1996 Nov-Dec;7(6):16-8.
Posit Aware. 1996.
PMID: 11363974
Effect of zidovudine postexposure prophylaxis on the development of HIV-specific cytotoxic T-lymphocyte responses in HIV-exposed healthcare workers.
Infect Control Hosp Epidemiol. 1999 Jun;20(6):428-30. doi: 10.1086/501646.
Infect Control Hosp Epidemiol. 1999.
PMID: 10395147
Evaluation of immunologic markers in cervicovaginal fluid of HIV-infected and uninfected women: implications for the immunologic response to HIV in the female genital tract.
J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Nov 1;16(3):161-8. doi: 10.1097/00042560-199711010-00004.
J Acquir Immune Defic Syndr Hum Retrovirol. 1997.
PMID: 9390567
Evaluation of the impact of highly active antiretroviral therapy on immune recovery in antiretroviral naive patients.
HIV Med. 2004 Jan;5(1):55-65. doi: 10.1111/j.1468-1293.2004.00186.x.
HIV Med. 2004.
PMID: 14731171
Free article.
Immunologic and virologic evaluation after influenza vaccination of HIV-1-infected patients.
AIDS. 1997 Jul;11(8):1013-21. doi: 10.1097/00002030-199708000-00010.
AIDS. 1997.
PMID: 9223736
Clinical Trial.
Latest opportunistic infection prevention guidelines.
Posit Aware. 1998 Jan-Feb;9(1):43-4.
Posit Aware. 1998.
PMID: 11365000
Lower CD4+ T lymphocyte nadirs may indicate limited immune reconstitution in HIV-1 infected individuals on potent antiretroviral therapy: analysis of immunophenotypic marker results of AACTG 5067.
J Clin Immunol. 2005 Mar;25(2):106-15. doi: 10.1007/s10875-005-2816-0.
J Clin Immunol. 2005.
PMID: 15821887
Clinical Trial.
Neurocognitive effects of treatment interruption in stable HIV-positive patients in an observational cohort.
Neurology. 2010 Apr 20;74(16):1260-6. doi: 10.1212/WNL.0b013e3181d9ed09. Epub 2010 Mar 17.
Neurology. 2010.
PMID: 20237308
Free PMC article.
Clinical Trial.
Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study.
Lancet HIV. 2021 Nov;8(11):e668-e678. doi: 10.1016/S2352-3018(21)00184-3. Epub 2021 Oct 14.
Lancet HIV. 2021.
PMID: 34656207
Clinical Trial.
Cite